Details of Disease

General Information of Disease (ID: DISKUCQY)

Disease Name Aggressive cancer
Disease Class 2A00-2F9Z: Solid tumour/cancer
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISKUCQY: Aggressive cancer
ICD Code
ICD-11
ICD-11: 2A00-2F9Z
ICD-10
ICD-10: R45.6
ICD-9
ICD-9: 140-229
Expand ICD-11
'MB23.0
Expand ICD-10
'R45.6
Expand ICD-9
140,141,142,143,144,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 75 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
A295 DM55GO2 IND submitted Small molecule [1]
A435 DMJCL7X IND submitted Small molecule [1]
Tusamitamab ravtansine DMMPSA1 Phase 3 Antibody drug conjugate [2]
AMG 193 DMU9K8N Phase 2 Small molecule [3]
ASP0739 DMWSZY9 Phase 2 Cell therapy [4]
AZD8205 DMXKH0S Phase 2 Antibody drug conjugate [5]
AZD8853 DMBKP7B Phase 2 NA [6]
AZD9574 DMKAIR9 Phase 2 Small molecule [7]
BNT122 DMD0FNY Phase 2 Vaccine [8]
BNT142 DM4E22R Phase 2 Antibody [9]
BNT151 DMZKVIE Phase 2 mRNA (modRNA) [10]
BNT211 DM0RZTZ Phase 2 Cell therapy [11]
GSK4428859 DMIOIU8 Phase 2 Antibody [12]
mRNA-4359 DMLJZ5N Phase 2 Vaccine [13]
NGM707 DMA5DDI Phase 2 Antibody [14]
SAR444200 DM7J5H0 Phase 2 Nanobody [15]
SAR445877 DM91KZL Phase 2 Fusion protein [16]
TAK-280 DM08RE5 Phase 2 NA [17]
TT20X DMHGI09 Phase 2 CAR-T cell therapy [18]
AdAPT-001 DMKW8LZ Phase 1/2 Oncolytic virus [19]
ASP1570 DMBUOUV Phase 1/2 Small molecule [20]
Camonsertib DMOPPXY Phase 1/2 Small molecule [21]
CM24 DM8CROB Phase 1/2 Antibody [22]
CX2029 DMYTTBK Phase 1/2 Antibody drug conjugate [23]
Modakafusp alfa DMB5N7B Phase 1/2 NA [24]
RC118 DMU25QT Phase 1/2 Antibody drug conjugate [25]
TAK-186 DM6XL9A Phase 1/2 NA [26]
TRQ-1501 DM2QS4B Phase 1/2 Cell therapy [27]
225Ac-PSMA-617 DMG77MF Phase 1 NA [28]
A289 DMO4DSH Phase 1 Monoclonal antibody [1]
A296 DMY4DUY Phase 1 Small molecule [1]
A337 DMXWFP2 Phase 1 Bispecific antibody [1]
A380 DMXOZDP Phase 1 Small molecule [1]
A400 DMQ0YH2 Phase 1 Small molecule [1]
A416 DMBQXAX Phase 1 Small molecule [1]
ACE1702 DMHI7DX Phase 1 Antibody [29]
AMG 794 DMS22QR Phase 1 Bispecific T-cell engager [30]
AN0025 DMGSYPY Phase 1 Small molecule [31]
ASP2074 DMY06PB Phase 1 Antibody [32]
ASP3082 DMDRXLL Phase 1 Small molecule [33]
AZD9592 DMDPM67 Phase 1 NA [34]
BB-1701 DMOAK6T Phase 1 Antibody drug conjugate [35]
BNT152 DMKP9GO Phase 1 mRNA (modRNA) [36]
BNT153 DMD87T4 Phase 1 mRNA (modRNA) [36]
BNT221 DM1TL3W Phase 1 Cell therapy [37]
BNT313 DM4J9AI Phase 1 Antibody [38]
FID-007 DMQZCL5 Phase 1 NA [39]
GSK3537142 DMW0XQM Phase 1 NA [40]
GSK4381562 DM7E61Z Phase 1 Antibody [41]
NGM438 DM0LK0V Phase 1 Antibody [42]
NGM831 DMAPIXW Phase 1 Antibody [43]
NK100 DMC4HT7 Phase 1 Cell therapy [44]
PF-07209960 DM1W90B Phase 1 NA [45]
PF-07263689 DM93K1P Phase 1 Vaccine [46]
PF-07265028 DMJIXMO Phase 1 NA [47]
PF-07284892 DMQ6F8X Phase 1 Small molecule [48]
PF-07799544 DMAO10K Phase 1 Small molecule [49]
PF-07799933 DMHGA0S Phase 1 NA [50]
RG6344 DMLK2UK Phase 1 NA [51]
RG6392 DMIK6VG Phase 1 NA [51]
RG6411 DMUISAW Phase 1 NA [51]
RG6433 DMZM06U Phase 1 Small molecule [51]
RG6440 DMVQXFH Phase 1 Monoclonal antibody [51]
RG6524 DMT22UV Phase 1 Antibody [51]
SAR444881 DM105TB Phase 1 Antibody [52]
SAR446309 DMB5XRY Phase 1 NA [52]
SKB315 DMI0JT4 Phase 1 Antibody drug conjugate [53]
SQZ DMUS99F Phase 1 Vaccine [51]
TAK-103 DMGWDCW Phase 1 CAR-T cell therapy [54]
TAK-500 DMVZ2FG Phase 1 Antibody drug conjugate [55]
TT16 DM5YL4N Phase 1 CAR-T cell therapy [18]
XMT-2056 DM904CF Phase 1 Antibody-drug conjugate [56]
YH001 DMHQNVR Phase 1 Antibody [57]
YH002 DMWVRHD Phase 1 Antibody [58]
YH003 DM84TF8 Phase 1 Antibody [59]
------------------------------------------------------------------------------------
⏷ Show the Full List of 75 Drug(s)
This Disease is Treated as An Indication in 3 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BNT212 DM27NTT Preclinical Cell therapy [60]
DYV800 DM2NP0W Preclinical NA [61]
IM1240 DMTV0DK Preclinical Antibody [62]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 6 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
YH006 DMRECC2 Investigative Bispecific antibody [63]
YH008 DMTIP9S Investigative Bispecific antibody [64]
YH010 DMA1T66 Investigative Antibody [65]
YH011 DM3JEEU Investigative Antibody [64]
YH012 DMG3WBJ Investigative Bispecific antibody-drug conjugate [64]
YH013 DMQ0474 Investigative Bispecific antibody-drug conjugate [64]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Clinical pipeline report, company report or official report of Klus Pharma
2 ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05094336) A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT04939701) A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1. U.S.National Institutes of Health.
5 ClinicalTrials.gov (NCT05123482) A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies. U.S.National Institutes of Health.
6 ClinicalTrials.gov (NCT05397171) A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours. U.S.National Institutes of Health.
7 ClinicalTrials.gov (NCT05417594) A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1). U.S.National Institutes of Health.
8 ClinicalTrials.gov (NCT03289962) A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors. U.S.National Institutes of Health.
9 ClinicalTrials.gov (NCT05262530) First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors. U.S.National Institutes of Health.
10 ClinicalTrials.gov (NCT04455620) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors. U.S.National Institutes of Health.
11 ClinicalTrials.gov (NCT04503278) Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors. U.S.National Institutes of Health.
12 Clinical pipeline report, company report or official report of GlaxoSmithKline
13 ClinicalTrials.gov (NCT05533697) Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors. U.S.National Institutes of Health.
14 ClinicalTrials.gov (NCT04913337) A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies. U.S.National Institutes of Health.
15 ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health.
16 ClinicalTrials.gov (NCT05584670) A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
17 ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
18 Clinical pipeline report, company report or official report of Tessa Therapeutics
19 ClinicalTrials.gov (NCT04673942) A Phase 1/2, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors. U.S.National Institutes of Health.
20 ClinicalTrials.gov (NCT05083481) A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
21 ClinicalTrials.gov (NCT04972110) Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC). U.S.National Institutes of Health.
22 ClinicalTrials.gov (NCT04731467) A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
23 ClinicalTrials.gov (NCT03543813) A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). U.S.National Institutes of Health.
24 ClinicalTrials.gov (NCT04157517) An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
25 ClinicalTrials.gov (NCT05205850) An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2. U.S.National Institutes of Health.
26 ClinicalTrials.gov (NCT04844073) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
28 ClinicalTrials.gov (NCT04597411) AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy. U.S.National Institutes of Health.
29 ClinicalTrials.gov (NCT04319757) A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors. U.S.National Institutes of Health.
30 ClinicalTrials.gov (NCT05317078) Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications. U.S.National Institutes of Health.
31 ClinicalTrials.gov (NCT04975958) An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
32 ClinicalTrials.gov (NCT05646797) A Phase 1/1b Study of ASP2074 in Participants With Metastatic or Locally Advanced Solid Tumors. U.S.National Institutes of Health.
33 ClinicalTrials.gov (NCT05382559) A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. U.S.National Institutes of Health.
34 ClinicalTrials.gov (NCT05647122) A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
35 ClinicalTrials.gov (NCT04257110) A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors. U.S.National Institutes of Health.
36 ClinicalTrials.gov (NCT04710043) Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors. U.S.National Institutes of Health.
37 ClinicalTrials.gov (NCT04625205) An Open-label, Phase I Study of NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma. U.S.National Institutes of Health.
38 ClinicalTrials.gov (NCT05435339) First-in-Human, Open-label, Dose-Escalation Trial With an Expansion Cohort to Evaluate the Safety of GEN1053 as Monotherapy in Subjects With Malignant Solid Tumors. U.S.National Institutes of Health.
39 ClinicalTrials.gov (NCT03537690) A Phase I Study of FID-007 in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
40 Clinical pipeline report, company report or official report of GlaxoSmithKline
41 ClinicalTrials.gov (NCT05277051) A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors. U.S.National Institutes of Health.
42 ClinicalTrials.gov (NCT05311618) A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
43 ClinicalTrials.gov (NCT05215574) A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
44 ClinicalTrials.gov (NCT03319459) FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
45 ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
46 ClinicalTrials.gov (NCT05061537) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
47 ClinicalTrials.gov (NCT05233436) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
48 ClinicalTrials.gov (NCT04800822) A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health.
49 ClinicalTrials.gov (NCT05538130) A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health.
50 ClinicalTrials.gov (NCT05355701) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS. U.S.National Institutes of Health.
51 Clinical pipeline report, company report or official report of Roche
52 Clinical pipeline report, company report or official report of Sanofi
53 ClinicalTrials.gov (NCT05367635) A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2. U.S.National Institutes of Health.
54 ClinicalTrials.gov (NCT05164666) An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
55 ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
56 ClinicalTrials.gov (NCT05514717) A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2. U.S.National Institutes of Health.
57 ClinicalTrials.gov (NCT04699929) A Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability,Efficacy and Pharmacokinetics of YH001 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
58 ClinicalTrials.gov (NCT04353102) A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies. U.S.National Institutes of Health.
59 ClinicalTrials.gov (NCT05017623) A Multicenter, Open-label, Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH003 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
60 Clinical pipeline report, company report or official report of Biontech
61 Clinical pipeline report, company report or official report of Dyve Biosciences
62 Clinical pipeline report, company report or official report of Purple
63 Clinical pipeline report, company report or official report of Biocytogen
64 Clinical pipeline report, company report or official report of Biocytogen
65 Clinical pipeline report, company report or official report of Biocytogen